PDF(Pubmed)
Abstract：
Lung cancer is a leading cause of cancer-related morbidity and mortality worldwide. Metastases in the brain are a common hallmark of advanced stages of the disease, contributing to a dismal prognosis. Lung cancer can be broadly classified as either small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC). NSCLC represents the most predominant histology subtype of lung cancer, accounting for the majority of lung cancer cases. Recent advances in molecular genetics, coupled with innovations in small molecule drug discovery strategies, have facilitated both the molecular classification and precision targeting of NSCLC based on oncogenic driver mutations. Furthermore, these precision-based strategies have demonstrable efficacy across the blood-brain barrier, leading to positive outcomes in patients with brain metastases. This review provides an overview of the clinical features of lung cancer brain metastases, as well as the molecular mechanisms that drive NSCLC oncogenesis. We also explore how precision medicine-based strategies can be leveraged to improve NSCLC brain metastases.
摘要：
肺癌是全球癌症相关发病率和死亡率的主要原因。大脑转移是疾病晚期的常见标志，导致令人沮丧的预后。肺癌可大致分类为小细胞肺癌(SCLC)或非小细胞肺癌(NSCLC)。NSCLC代表了肺癌最主要的组织学亚型，占肺癌病例的大多数。分子遗传学的最新进展，再加上小分子药物发现策略的创新，基于致癌驱动突变，促进了NSCLC的分子分类和精确靶向。此外，这些基于精度的策略在血脑屏障上具有明显的功效，导致脑转移患者的积极结果。本文综述了肺癌脑转移的临床特点。以及驱动NSCLC肿瘤发生的分子机制。我们还探讨了如何利用基于精准医学的策略来改善NSCLC脑转移。
